2025-12-28 - Analysis Report
Okay, here's a report analyzing Eli Lilly and Co. (LLY) based on the data provided, followed by a comprehensive summary.

**1) Return Rate Comparison (LLY vs. S&P 500)**

*   **LLY Overview:** Eli Lilly and Co. is a global pharmaceutical company discovering, developing, and marketing medicines.

*   **Cumulative Returns:**
    *   LLY: 307.99%
    *   VOO (S&P 500): 103.21%

*   **Divergence:** LLY has significantly outperformed the S&P 500, with a divergence of 204.7%. The relative divergence of 84.5 indicates that the current divergence is in the top percentile of its historical fluctuation range. This suggests strong outperformance relative to its usual performance compared to the S&P 500.

*   **Alpha, Beta Analysis:**

    | Year       | CAGR   | MDD   | Alpha  | Beta | Cap(B) |
    |------------|--------|-------|--------|------|--------|
    | 2015-2017  | 11.0%  | 76.1% | -17.0% | -0.0 | 75.7   |
    | 2016-2018  | 39.0%  | 68.9% | 24.0%  | -0.0 | 103.7  |
    | 2017-2019  | 41.0%  | 68.9% | 19.0%  | 0.4  | 117.8  |
    | 2018-2020  | 34.0%  | 79.8% | 10.0%  | 0.4  | 151.4  |
    | 2019-2021  | 53.0%  | 79.8% | 7.0%   | 0.5  | 247.6  |
    | 2020-2022  | 64.0%  | 79.8% | 65.0%  | 0.4  | 328.0  |
    | 2021-2023  | 125.0% | 78.9% | 124.0% | 0.2  | 522.6  |
    | 2022-2024  | 134.0% | 81.2% | 113.0% | 0.2  | 692.1  |
    | 2023-2025  | 199.0% | 83.5% | 132.0% | 0.2  | 966.2  |

    *   **CAGR:** The Compounded Annual Growth Rate shows substantial growth in recent years, particularly from 2021 onwards.
    *   **MDD:** The Maximum Drawdown indicates significant potential loss from peak to trough.
    *   **Alpha:**  Positive alpha values indicate that LLY has generally outperformed its benchmark (S&P 500), with especially strong performance in the 2020-2025 period.
    *   **Beta:** Beta values around 0.2 to 0.5 suggests LLY is less volatile than the market. A negative Beta implies that LLY’s price has a tendency to move in the opposite direction to the market (S&P 500).
    *   **Cap(B):** Market capitalization of the company. LLY has experienced substantial growth in market capitalization.

**2) Recent Stock Price Fluctuations**

*   **Current Price:** 1077.75
*   **Last Market Change:** +0.07 compared to the previous close. This very slight change doesn't immediately indicate a significant fluctuation event.
*   **Moving Averages:**
    *   5-day SMA: 1074.86
    *   20-day SMA: 1040.49
    *   60-day SMA: 952.21

    The stock price is above all three moving averages, which is generally considered a bullish signal.  The fact that the 5-day SMA is above the 20-day SMA, and the 20-day SMA is above the 60-day SMA further supports a short-term upward trend.

**3) Index Indicators & Expected Return**

*   **MRI (Market Risk Indicator):** 1.0 (High Investment Recommended). This suggests the model considers LLY a good investment at this time.
*   **RSI (Relative Strength Index):** 69.37.  This indicates that LLY is approaching overbought territory (typically above 70). This suggests price may correct downward soon.
*   **PPO (Percentage Price Oscillator):** -0.03. This is close to zero, indicating that current price is near the average price from the past several periods.
*   **Hybrid Signal:** "cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)" - This reinforces the investment recommendation.  It suggests a strong buy signal with no cash allocation advised. The recommendation to invest 0.8% of total investment monthly is a small addition to the investment to continue to grow.
*   **Recent Relative Divergence Change:** 5.8 (+).  A positive change indicates recent short-term upward momentum.
*   **Expected Return:** 49.2%.  This is a high expected excess return compared to the S&P 500, suggesting significant potential for future growth.

**4) Recent News & Significant Events**

*   **Positive Headlines:**
    *   "Eli Lilly (LLY) a Top Stock Split Candidate in 2026" - A stock split is often seen as a bullish sign, indicating management believes the stock price will continue to rise.
    *   "Eli Lilly Stock (LLY) Holds Near $1,078 After Friday’s Close as GLP‑1 Pricing, Pill Competition, and Retatrutide Data Shape the 2026 Outlook" - Suggests a positive outlook due to drug pricing, competition, and promising data.
    *   "Cwm LLC Has $75.20 Million Stock Position in Eli Lilly and Company $LLY" - Shows institutional investment confidence.
*   **Mixed/Concerning Headlines:**
    *   "Eli Lilly: Mr. Market Finally Woke Up, But I'm Not Out Yet (Rating Downgrade)" - This suggests that while the analyst remains invested, the rating downgrade indicates some concerns about the stock's current valuation or future prospects.
    *   "Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip?" - A price cut, even if strategic, can be initially viewed negatively by the market. This headline presents it as a potential buying opportunity.

**4-2) Analyst Opinions**

*   **Consensus:** Buy (Mean: 1.70)
*   **Target Price:** Average: $1093.22, High: $1500.00, Low: $770.00
*   **Recent Rating Changes:** No specific changes provided. The analyst consensus indicates that most analysts have a buy rating. The target price is $1093.22 which indicates a slight upward movement can happen.

**5) Recent Earnings Analysis**

| 날짜       | EPS   | 매출     |
|------------|-------|----------|
| 2025-10-30 | 6.22  | 17.60 B$ |
| 2025-08-07 | 6.30  | 15.56 B$ |
| 2025-05-01 | 3.07  | 12.73 B$ |
| 2024-10-30 | 1.08  | 11.44 B$ |
| 2025-10-30 | 1.08  | 11.44 B$ |

*   The table shows a strong trend of increasing EPS and revenue over the reported quarters.
* The date 2025-10-30 is repeated.
*   The most recent EPS of 6.22 is similar to 6.3. However, the most recent sales is $17.60 billion, which is significantly higher.

**6) Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|---------------|
| 2025-09-30   | $17.60B    | 82.91%        |
| 2025-06-30   | $15.56B    | 84.27%        |
| 2025-03-31   | $12.73B    | 82.53%        |
| 2024-12-31   | $13.53B    | 82.24%        |
| 2024-09-30   | $11.44B    | 81.02%        |

*   Revenue has consistently increased over the past five quarters.
*   Profit margins are exceptionally high and relatively stable, indicating strong profitability and efficient cost management.

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-09-30   | $23.79B    | 23.46%  |
| 2025-06-30   | $18.27B    | 30.98%  |
| 2025-03-31   | $15.76B    | 17.50%  |
| 2024-12-31   | $14.19B    | 31.07%  |
| 2024-09-30   | $14.24B    | 6.81%   |

*   Equity has generally increased, indicating a healthy financial position.
*   ROE (Return on Equity) is quite volatile, but the most recent values are very strong, suggesting effective use of shareholder equity to generate profits.

**7) Comprehensive Analysis (Summary)**

Eli Lilly (LLY) is demonstrating very strong performance and growth. It has significantly outperformed the S&P 500, driven by rising revenue, high profit margins, and promising drug development. Analyst consensus is generally positive.  The technical indicators present a mixed view, with a high MRI suggesting good investment potential, but a high RSI indicates it may be overbought. The recent price fluctuations and news suggest some short-term volatility, particularly related to drug pricing and analyst rating changes.

**Overall Recommendation:**

The data suggests that LLY is a strong company with excellent recent performance.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.